- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
- Drug
- Lead sponsor
- Delta-Fly Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 33 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Myeloid Leukemia
- Interventions
- A arm (DA-90), B arm (DAC), A arm (CLAG-M), B arm (FLAG-IDA)
- Drug
- Lead sponsor
- Polish Adult Leukemia Group
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Leukemia
- Interventions
- CLAG Regimen, Gleevec®
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Acute Myeloid Leukemia, Adult, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, Relapsed, Adult
- Interventions
- Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO)
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Interventions
- Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen, Venetoclax
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Boston, Massachusetts
- Conditions
- Relapsed Adult AML, Refractory AML
- Interventions
- Navitoclax Dose Level 1, Navitoclax Dose Level 0, Navitoclax Dose Level 2, Venetoclax Dose Level -1, Venetoclax Dose Levels 0 to 2, Cladribine, Cytarabine (Cladribine Low Dose Cytarabine Backbone), Cytarabine (CLAG-M Backbone), Mitoxantrone, Granulocyte Colony-Stimulating Factor
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Chronic Myeloid Leukemia, Blast Crisis, Acute Myeloid Leukemia
- Interventions
- Imatinib Mesylate, CLAG
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Leukemia
- Interventions
- filgrastim, cladribine, cytarabine, imatinib mesylate
- Biological · Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Acute Myeloid Leukemia, Myeloid Neoplasm
- Interventions
- Liposome-encapsulated Daunorubicin-Cytarabine, Cladribine, Cytarabine, Recombinant Granulocyte Colony-Stimulating Factor, Mitoxantrone, Questionnaire Administration, Quality-of-Life Assessment
- Drug · Biological · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Interventions
- Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen, Cladribine and Cytarabine (CLLDAC) Regimen
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin